Champions Oncology (NASDAQ: CSBR) — Perfil da empresa, notícias e dados financeiros
Champions Oncology develops technology solutions for personalized oncology drug development using its proprietary TumorGraft platform.
Champions Oncology
Champions Oncology (NASDAQ:CSBR) specializes in developing advanced technology solutions and services to personalize the development and use of oncology drugs. As the company focuses on translational oncology research, Champions Oncology leverages its proprietary TumorGraft platform – a novel approach that involves transplanting human tumors into immunodeficient mice – to guide the development of therapeutic and diagnostic solutions for cancer patients. Operating with the objective to enhance drug development through precise models that mimic human cancer environments, Champions Oncology's work spans preclinical mouse models to phase II/III clinical trials, aiming to improve outcomes for cancer patients by identifying the most effective cancer treatments.
Resumo
Operações
Produtos e/ou serviços de Champions Oncology
- Translational oncology solutions linking laboratory findings with clinical trial outcomes.
- Personalized oncology services offering tailored treatment plans.
- Preclinical mouse models for cancer research and drug development.
- Comprehensive tumor profiling services for complex cancer cases.
- Pharmacology and toxicology studies to support drug approval processes.
- Bioinformatics services, analyzing complex data for drug discovery and development.
equipe executiva do Champions Oncology
- Ronnie MorrisExecutive Chair
- Robert BraininCEO & Director
- David Barry MillerChief Financial Officer
- Maria ManciniChief Operating Officer
- Marianna ZipetoExecutive Vice President of Growth, Strategy & Enablement
Principais indicadores financeiros
Resultados divulgados pela Champions Oncology, em USD.
- Cap. de mercado
- 67,2 mi
- Receita (TTM)
- 60,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- -1.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 59,4 mi | -1,1 mi | -1,2 mi | |
| 56,9 mi | 4,8 mi | 4,7 mi | |
| 50,2 mi | -6,9 mi | -7,3 mi | |
| 53,9 mi | -4,4 mi | -5,3 mi |